Looking for Alcohol Treatment Information?

You can receive independent, expert advice on alcohol rehabilitation and rehab centres by telephoning DryOutNow.com on 0845 370 0203.

The most important consideration in choosing a rehab centre is to match the individual to the rehab centre that is most likely to lead to a successful outcome.

DryOutNow.com can provide an assessment of all your needs and a recommendation regarding the most effective rehab placement for you, given your particular circumstances. We can provide fast, immediate access to alcohol treatment.

Alcohol Treatment Research: Extended treatment with combination medication for opioid addicted youths shows benefit

Adolescents addicted to opioids who received continuing treatment with the combination medication buprenorphine-naloxone had lower rates of testing positive or reporting use of opioids compared to youths who went through a short-term detoxification program using the same medication, according to a study in the November 5 issue of JAMA.

Recent data suggest that abuse of opioids, including heroin and prescription pain-relief drugs, is increasing among adolescents, according to background information in the article. "The usual treatment for opioid-addicted youth is short-term detoxification and individual or group therapy in residential or outpatient settings over weeks or months. Clinicians report that relapse is high, yet many programs remain strongly committed to this approach and, except for treating withdrawal, do not use agonist [a drug that mimics the action of a naturally occurring substance] medication," the authors write.

George Woody, M.D., of the University of Pennsylvania, Philadelphia, and colleagues conducted a study comparing outcomes of treating opioid addiction among adolescents with extended treatment using buprenorphine-naloxone vs. short-term detoxification. Buprenorphine is an oral medication that acts by relieving the symptoms of opiate withdrawal. Naloxone is a drug that prevents or reverses the effects of opioids if it is injected. The study included 152 patients, age 15 to 21 years. Patients in the 12-week buprenorphine-naloxone group were prescribed up to 24 mg. per day for 9 weeks and then tapered to week 12; patients in the detox group were prescribed up to 14 mg. per day and then tapered to day 14.

All were offered weekly individual and group counselling.

The researchers found that overall, patients in the detox group had higher proportions of opioid-positive urine test results at weeks 4 and 8 but not at week 12. At week 4, 61 percent of detox patients had positive results vs. 26 percent of the 12-week buprenorphine-naloxone patients. At week 8, 54 percent of detox patients had positive results vs. 23 percent of 12-week buprenorphine-naloxone patients. At week 12, 51 percent of detox patients had positive results vs. 43 percent of buprenorphine-naloxone patients, who by that time had been tapered off their medication.

By week 12, 20.5 percent of detox patients remained in treatment vs. 70 percent of 12-week buprenorphine-naloxone patients. During weeks 1 through 12, patients in the 12-week buprenorphine-naloxone group reported less use of opioids, cocaine and marijuana, less injecting, and less need for additional addiction treatment. High levels of opioid use occurred in both groups at follow-up.

"Taken together, these data show that stopping buprenorphine-naloxone had comparably negative effects in both groups, with effects occurring earlier and with somewhat greater severity in patients in the detox group," the authors write.

"Because much opioid addiction treatment has shifted from inpatient to outpatient where buprenorphine-naloxone can be administered, having it available in primary care, family practice, and adolescent programs has the potential to expand the treatment options currently available to opioid-addicted youth and significantly improve outcomes. Other effective medications, or longer and more intensive psychosocial treatments, may have similarly positive results. Studies are needed to explore these possibilities and to assess the efficacy and safety of longer-term treatment with buprenorphine for young individuals with opioid dependence."

Reference

Woody et al. Extended vs Short-term Buprenorphine-Naloxone for Treatment of Opioid-Addicted Youth: A Randomized Trial.' JAMA, 2008; 300 (17): 2003-2011

DryOutNow.com provides highly practical help for people with alcohol problems, their friends and relatives. DryOutNow.com also provides free resources for healthcare professionals such as medical information and alcohol treatment guidelines.

Other Alcohol Treatment Research Articles

• Poor Alcohol Regulation could cost up to 250,000 lives, doctors predict.
• Technology improves treatment options for drug users
• Department promoting early substance use screening process
• Alcohol tax increases deter drinking
• DrugScope welcomes report on 'neglected issue' of prescription and over-the-counter medication depen
• DrugScope responds to NTA figures on young people in treatment for substance misuse
• Concerns over trends in Ketamine use
• Try science when 'just saying no' isn't enough
• More action needed to tackle alcohol misuse, says BMA
• Alkermes initiates clinical trial for ALKS 33, a novel oral molecule with potential benefits in addi
• Genetic markers identified for alcohol response in UCSF Gallo study
• NIDA Monitoring the Future Survey, Results published
• Technology can help addicts trying to quit
• Study assesses success of anti meth adverts
• All patients should be asked about alcohol and drug abuse, says The American College of Obstetrician
• Researchers must tap into the language of intoxication
• Report points to lack of public awareness of health guidelines
• Reward stress link points to new targets for treating addiction
• SAMHSA releases new data on drug related hospital emergency department visits
• National rates of co occurring substance use and mental disorders call for better integration of men

Latest Alcohol Policy Related Articles

• Leeds counts 438GBP million economic and social cost of alcohol-related problems
• Pablo and FRANK - the new cocaine campaign
• Cannabis upgraded to Class B drug
• DrugScope welcomes report on 'neglected issue' of prescription and over-the-counter medication depen
• Tougher health and safety law demands tougher drugs policies, says drug testing company
• Time's up for irresponsible drink deals
• More action needed to tackle alcohol misuse, says BMA
• New report reveals that five million people participate in self help groups each year
• Make Scotlands roads safer, reduce drink driving limits, says BMA Scotland
• Study will seek to break cycle of chemical dependence and incarceration
• More advice on alcohol and healthy living from UK Department of Health
• Working towards recovery, Getting problem drug users into jobs, UKDPC report released
• More support needed for employers to hire addicts, says research
• Study shows link between number of alcohol retailers and youth injuries
• European project to study relationship between ADHD and substance abuse
• Two few treatments centres says former government adviser
• BMA Scotland recently published an action plan to tackle alcohol misuse
• WHO to hold public hearing on ways of reducing the harmful use of alcohol
• Public policy measures on alcohol price and availability would be more effective than clinical treat
• Licensing act could be affecting alcohol-related hospital admissions